Outcomes of intravitreal rituximab treatment
| Variable | Number of eyes (%) or range (median) |
|---|---|
| Treated eyes (n=48) | |
| Remission | |
| Complete | 31 (64.6) |
| Partial | 11 (22.9) |
| None | 4 (8.3) |
| Not applicable | 2 (4.2) |
| Complications | |
| Related to treatment (or unable to exclude treatment as a cause) | 12 (25.0) |
| Cataract | 9 (18.8) |
| Elevated intraocular pressure | 2 (4.2) |
| Anterior uveitis | 1 (2.1) |
| Vitreous haemorrhage | 1 (2.1) |
| Retinal detachment | 1 (2.1) |
| None | 36 (75.0) |
| Not related to treatment | 6 (12.5) |
| Keratopathy | 2 (4.2) |
| Maculopathy | 2 (4.2) |
| Glaucoma | 1 (2.1) |
| Choroidal neovascularisation | 1 (2.1) |
| Retinal detachment | 1 (2.1) |
| Eyes with complete remission (n=31) | |
| Number of injections to remission | 1–10 (3) |
| Relapse | 6 (19.4) |
| Time to relapse (months from day of first treatment) | 5–26 (17.5) |